Mersana Therapeutics Inc (MRSN)

$0.53 +0.01 (0.98%)
Market Cap 65.87M
Revenue (ttm) 36.86M
Net Income (ttm) -171.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.74%
Debt to Equity Ratio 24.25
Volume 6,725,200
Avg Vol 5,774,102
Day's Range N/A - N/A
Shares Out 123.53M
Stochastic %K 10%
Beta 1.39
Analysts Strong Sell
Price Target $5.00

Latest News on MRSN

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:05 PM EST - 15 days ago

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 8:00 AM EST - 24 days ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 12:49 PM EST - 6 weeks ago

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Jan 10, 2025, 6:02 AM EST - 6 weeks ago

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Jan 10, 2025, 6:00 AM EST - 6 weeks ago

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Dec 19, 2024, 7:17 AM EST - 2 months ago

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 1:26 PM EST - 3 months ago

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 3 months ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Nov 6, 2024, 8:00 AM EST - 3 months ago

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 12:55 PM EDT - 6 months ago

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Aug 13, 2024, 7:00 AM EDT - 6 months ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

Aug 6, 2024, 8:00 AM EDT - 7 months ago

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

Mersana Therapeutics to Present at Upcoming Investor Conferences

May 22, 2024, 8:00 AM EDT - 9 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

May 9, 2024, 2:09 PM EDT - 10 months ago

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

May 9, 2024, 6:59 AM EDT - 10 months ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 3, 2024, 4:30 PM EDT - 10 months ago

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

May 2, 2024, 8:00 AM EDT - 10 months ago

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 2:10 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

Feb 1, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 5, 2024, 8:01 AM EST - 1 year ago

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 1:34 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Oct 31, 2023, 4:30 PM EDT - 1 year ago

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Mersana Therapeutics Announces Changes in Leadership

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Mersana Therapeutics Announces Changes in Leadership

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Jul 27, 2023, 7:06 AM EDT - 1 year ago

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

Jun 27, 2023, 5:45 AM EDT - 1 year ago

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold

Jun 15, 2023, 8:03 AM EDT - 1 year ago

US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold

Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events

Jun 15, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

Jun 15, 2023, 7:30 AM EDT - 1 year ago

Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials

Mersana Therapeutics, Inc. (MRSN) Q1 2023 Earnings Call Transcript

May 9, 2023, 1:45 PM EDT - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q1 2023 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

May 9, 2023, 7:00 AM EDT - 1 year ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

May 3, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

May 2, 2023, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

Apr 26, 2023, 4:05 PM EDT - 1 year ago

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

Mersana Therapeutics: Unrecognized Promise In UpRi's Cancer Fight

Apr 3, 2023, 5:20 PM EDT - 2 years ago

Mersana Therapeutics: Unrecognized Promise In UpRi's Cancer Fight

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

Mar 13, 2023, 7:30 AM EDT - 2 years ago

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

Mersana Therapeutics Provides Statement About SVB

Mar 10, 2023, 7:10 PM EST - 2 years ago

Mersana Therapeutics Provides Statement About SVB

Mersana Therapeutics, Inc. (MRSN) Q4 2022 Earnings Call Transcript

Feb 28, 2023, 10:50 AM EST - 2 years ago

Mersana Therapeutics, Inc. (MRSN) Q4 2022 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 7:00 AM EST - 2 years ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Feb 21, 2023, 8:00 AM EST - 2 years ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

Jan 25, 2023, 8:00 AM EST - 2 years ago

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors